Tango Therapeutics (TNGX) · vopimetostat
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2026
we anticipate providing a safety and efficacy update in 2026.
· filed · SEC filing
After
Stated timing: 2H 2026
Disclose vopimetostat lung cancer monotherapy data in 2H 2026
EX-99.1 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/TNGX-vopimetostat-2026-06-08, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/TNGX-vopimetostat-2026-06-08
Tango Therapeutics (TNGX) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.